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Summary 
 We determined the alleles of 5 polymorphic molecules including HA-1 and four 
adhesion molecules for 106 patients transplanted HLA-identical stem cell grafts and 
investigated the association of mismatches as rates of relapse and GVHD. All 106 
recipients underwent stem cell transplantation after myeloablative conditioning between 
1985 and 2002. Risk status of the disease at SCT was standard (n=63) and high (n=42). 
After SCT, 36, 49 and 33 developed acute GVHD, chronic GVHD and relapsed, 
respectively. Our patients relapsed at rates of 16.7% and 38.6% with one or more and 
without incompatibilities (P=0.013). The relapse rates of patients with CD62L, CD31 
codon 563, CD31 codon 125, HA-1 and CD49b incompatibilities were 5.9%, 11.8%, 
15.4%, 16.0% and 33.3% respectively. The frequency of acute GVHD did not differ 
regardless of incompatibilities.  
 In standard risk group, the accumulated relapse rates of 19 and 44 patients with and 
without mHag incompatibility were 22% and unexpected 66%, respectively (P=0.02). 
The probability of 12-year survival rates was 88% in the former and 66% in the latter 
patients (P=0.03). Our data suggests that incompatibility of CD62L, CD31 codon 563 
and CD31 codon 125 contribute to GVL effect rather than to GVHD, resulting in 
prolonged survival after HLA-identical SCT.  
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 Donor-derived T lymphocytes that cause graft-versus-host disease (GVHD) might also 
induce graft-versus-leukemia (GVL) reactivity in an HLA identical combination. Minor 
histocompatibility antigens that induce GVHD are potential candidates for a GVL effect 
after allogeneic stem cell transplantation (SCT).1-5)
 HA-1 is an established minor histocompatibility antigen (mHag) that was discovered 
by Goulmy et al.1.2) and polymorphic adhesion molecules including CD31, CD49b and 
CD62L are immunodominant mHags that contribute to acute GVHD in Japanese 6) and 
in Caucasian7-9) populations. 
 Since the GVL effects are similar in both populations whereas the incidence and 
severity of acute GVHD is low among Japanese after allogeneic SCT and DLI10, 11), the 
roles of mHags in Japanese patients might differ from that of Western SCT patients. We 
therefore investigated the association of mHag mismatches with, acute GVHD, as well 
as relapse and survival rates. 
 
Materials and Methods 
Patients 
 During May 1998, 2002 and 2004, we collected various samples from donors and 
recipients before myeloablative stem cell transplantation to analyze HA-1 and four 
polymorphic adhesion molecules. The patients underwent the procedure at Kanazawa 
University Hospital, Niigata University Medical and Dental Hospital and the University 
Hospital of Occupation and Environment Health. Patients transplanted before May 1998 
were also enrolled in this study. The peripheral blood cells from patients after SCT were 
of donor origin and nail or buccal membrane samples were collected as host cells. 
Primary physicians were asked to report three times regarding the outcomes of stem cell 
transplantation. All of the patients were followed up for at least 2 years after SCT. 
 Data included patient age, sex, diagnosis, stage of disease at transplantation, donor sex, 
date of transplant, conditioning regimen, GVHD prophylaxis, severity of acute and 
chronic GVHD, other major complications after transplantation, time of relapse, HLA 
serological identified antigens and allele type in 35 out of the patients. For patients with 
CML, the type of relapse (molecular, cytogenetic or hematological) during stable, 
accelerated or blast phases was included. Treatment-related information included donor 
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leukocyte infusion (DLI), chemotherapy and α-interferon therapy. The outcome of the 
treatment was assessed according to the severity of GVHD and the response of 
leukemia to DLI. Survival, morbidity and recurrence of leukemia also were evaluated. 
Table 1 shows the characteristics of 65 male and 41 female patients who were 
transplanted with stem cells from 60 HLA-A, -B, -DR matched related donors and from 
46 HLA-A, -B, -DR matched unrelated donors where 5 of the 60 and 30 of the 46 were 
allele type compatible donors. 
 Conditioning regimens consisted of 12 Gy fractionated TBI as 3 Gy x4 or 2Gy x6 in 
99 of 106 patients and 7 of the 106 patients received a non-TBI regimen. Stem cell 
sources were BM (88), PBSC (15) and both (3). Post transplant immunosuppression 
consisted of short-term MTX+CyA (98), short-term MTX+FK (5) and only CyA (3). 
None of the patients received T cell depleted marrow. 
 Table 1 describes the diagnoses of the patients. Patients at standard risk were defined 
as those transplanted at the 1st complete remission of acute leukemia, in the chronic 
phase of chronic myeloid leukemia and refractory anemia of myelodysplastic syndrome 
17). High-risk patients consisted of those who were not assessed as being of standard risk. 
Patients with complications included 36 who developed acute GVHD (≧2), 53 who 




 The Institutional Review Board of Kanazawa University Hospital has approved the use 
of DNA analysis for mHag typing. We obtained the written, informed consent of 
patients and donors to obtain DNA from their peripheral blood samples before 
transplantation. Peripheral blood and nail or buccal membranes were obtained from 
post-transplant patients. The former was used as donor cells and nail or buccal 
membrane, as host cells. 
Allele typing of HA-1 and four polymorphic adhesion molecules  
Alleles of HA-1 and four polymorphic molecules were typed as described by Maruya et 
al.6) Briefly, purified genomic DNA for HA-1 and the polymorphic adhesion molecules 
were amplified by PCR using sequence-specific primers (Table 2). Amplification 
proceeded in 50 μl of PCR buffer (Applied Biosystems, Foster City, CA USA), 
containing 10 mmol/L Tris-HCL (pH 8.3), 50 mmol/L KCL, 1.5mmol/L MgCl2, 0.2 
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mmol/L each of the 4 deoxyribonucleotides (Applied Biosystems), 20 pmol of each 
primer, and 1.25 units of Taq polymerase (AmpliTaq Gold; Applied Biosystems). Four 
micro liters of DNA (80 ng) was denatured at 98℃ for 5 minutes, and then 35 cycles of 
denaturation (96℃, 1 minute), annealing (58℃, 1 minute) and extension at 72℃ for 5 
minutes were applied using an automated PCR thermal cycler (PERKIN ELMER 
CETUS). 
 The PCR products (10μl) were digested with 5 U of Mva I for CD31 codon 125, Bfa I 
for CD31 codon 563, Mnl I for CD49b, Hph I for CD62L at 37℃ for 4 h and with 
Tsp45 I for HA-1 overnight. The fragments were resolved by electrophoresis on 10% 
polyacrylamide gels for 1 h at 150V. The RFLP profiles in the gel were visualized by 
silver staining. 
Diagnosis of incompatibility of each polymorphic molecule  
The combination of HA-1 positive recipients (HA-1H/R or HA-1H/H) and an HA-1 
negative donor (HA-1R/R) was defined as incompatible. HA-1 was restricted to HLA-A2, 
but patients with the other class Ⅰ superfamilies were also evaluated. The 
incompatibility of the other four polymorphic adhesion molecules was defined as a 
combination of HLA-restricted patients transplanted with material from CD31, CD49b, 
CD62L incompatible donors as defined by Maruya6). The CD31 molecules are restricted 
to the HLA-B44-like superfamily (B37, B41, B44, B45, B47, B49, B50, B60 and B61), 
CD49b molecules to the HLA-A3-like superfamily (A3, A11, A31, A33 and A*6861) 
and CD62L molecules to the HLA-A3-like or B44-like superfamilies or both.12)
Statistical analysis 
Acute GVHD was classified according to the described criteria13). Relapse was 
diagnosed as emerging original leukemic cells after allogeneic stem cell transplantation. 
Relapse rate between incompatible and compatible patients was compared by a 
chi-square test. Multivariate analysis performed with logistic regression analysis. 
Variables include mHag, standard risk at SCT, TBI regimen over 10 Gy, stem cell 
source (PBSC), UR-BMT, sex incompatibility, acute GVHD and chronic GVHD. 
Survival rates and curves were estimated using the Kaplan-Meier method and the 





Characteristics of mHag incompatible and compatible patients 
 Table 1 shows comparison between the two groups. 36 of 106 patients were 
incompatible with at least one of these molecules and the other 70 patients were 
compatible with the donor. The comparison revealed that the relapse rate was lower in 
the incompatible (n=36) than in the compatible (n=70) patients (P＜0.013), although the 
other characteristics were compatible. The distribution of HA-1 allele type compatibility 
was identical with published data in Japan.14) 
Multivariate analysis  
 Table 3 shows multivariate analysis. Incompatibility of at least one mHag was most 
powerful and significant factor to induce GVL effect among evaluated factors with 
logistic regression analysis. 
Difference of GVL effect among each mHag 
 Table4 shows different intensity of GVL effect among each mHag. Compared with 
compatible patients, the relapse rate was significantly low only those with CD62L 
incompatibilities. The relapse rate tended to be low in those with CD31 and HA-1 
incompatibility but not statistical significant. The relapse rate of HA-1 incompatible 
patients with HLA-A2 and with other HLA class 1 super families tended to be low 
(16.6% and 13.3%) but the value was not statistically significant due to the small 
numbers. Interestingly, the incidence of acute GVHD(≧Ⅱ) between compatible and 
incompatible patients did not differ. The incidence of a-GVHD of patients with CD62L, 
CD31 codon 563, CD31 codon 125, HA-1 and CD49b incompatibilities were 35.3%, 
35.3%, 30.8%, 32% and 33.3% respectively which were comparable to those of 
compatibilities. Table5 showed different effect on GVL and a-GVHD among each 
mHags. Mismatches of CD62L, CD31 codon 563 and CD31 codon 125 induce GVL 
effect rather than a-GVHD.  
Long-term effect 
 Figure 1 shows accumulated relapse rate and survival rate in standard risk group. The 
estimated 12-year accumulated relapse rates of incompatible and compatible patients 
were 22% and 68%, respectively (P=0.02). After treatment, the 15-year probability of 
survival among patients in the standard risk group who were incompatible and 
compatible was improved to 88% and that of compatible patients was 66% (P=0.03). In 
the high-risk group, there was no significant difference between compatible and 
incompatible group in the relapse rate. 
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  Discussion 
 We demonstrated here that mHag incompatibility in HLA-identical stem cell recipients 
could induce GVL effect rather than acute GVHD after myeloablative stem cell 
transplantation. Since neither an increase of acute GVHD nor fatal complications 
developed during long-term follow up in the standard risk group, these mHags except 
CD49b may be ideal targets for donor derived T cells after SCT. Difference of CD49b is 
not any influence on GVL. 
 In the standard risk group, the relapse rate in patients with mHag incompatibility was 
lower than that of compatible patients (14% vs. 44%, P=0.02). In the latter group, 18 
out of 41 patients relapsed after allogeneic SCT. Nine of the relapsed patients were 
CML. 4 were cytogenetic and 3 were hematological relapse at 2, 14, 21, 39, 16, 68 and 
132 months after SCT. The remaining two were blastic and extramedullary relapse at 22 
and 36 months after SCT. Six of the 7 CML in chronic phase relapse were treated with 
DLI and the other one patient discontinued CyA to enhance the GVL effect. All of the 7 
CML patients achieved CR 2 to 6 months after DLI. The other nine of the 18 patients 
with relapse died due to relapse-related complications at 8, 32, 34, 43, 44, 48, 55, 59 
and 122 months after SCT. Interestingly none of the 7 CML patients with mHag 
incompatibilities in the standard risk group has relapsed. These suggest that mHag 
incompatibility induce prolonged anti-leukemia effect and induce long-term survivors 
after SCT.   
 In contrast to the study by Goulmy et al., our data did not show any increase in acute 
GVHD. These findings are compatible with those of Murata et al.14), which shows that 
HA-1 mismatch is not significantly associated with acute GVHD in Japanese patients6). 
The difference is probably due to intensified immunosuppressants for GVHD 
prophylaxis and smaller number of mHag contributing to GVHD in Japan than in 
Western counties. Goulmy et al. reported that recipient incompatibility with HA-1 is 
associated with the acute GVHD development since acute GVHD （≧2） developed in 
all HA-1- positive adult patients (n=10) who received marrow from a HA-1-negative 
donor. However, they received either MTX or CyA as GVHD prophylaxis. Among our 
patients, 103 of 106 received short-term MTX+CyA (98) or short-term MTX+FK 506 
(5) as prophylaxis for acute GVHD. Since the combination of MTX+CyA significantly 
decreases the incidence of acute GVHD compared with either MTX or CyA alone, the 
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strength of the association might be lower in patients who received either MTX+CyA or 
FK506 than in those who received either MTX or CyA. 
 Recently, a large-scale study has performed to know the association of ethnicity and 
the incidence of GVHD and revealed that lower risk of acute GVHD and early 
post-transplantation toxicity in Japanese and Scandinavian populations15) which suggest 
to a less diverse genetic background among HLA-identical pairs in Japan.  A 
large-scale survey of Japanese patients transplanted from HLA-identical sibling16) and 
HLA identical unrelated donors17) have a similar GVL effect with lower incidence of 
a-GVHD than that of Western countries. Furthermore, the results of donor leukocytes 
infusion for relapsed patients showed similar GVL effect with relatively low incidence 
of acute GVHD in Japan compared to Western country.10) These results together with 
our data suggested the number of mismatched mHag is even small, these molecules 
have enough power to induce GVL effect rather than a-GVHD in Japanese patients 
transplanted from HLA identical pairs.  
 Among the four polymorphic adhesion molecules, relapse rate were significantly low 
in patients with CD62L-incompatibility. Mismatches of CD31 cordon 563 and CD31 
cordon 125 also induce GVL effect rather than acute GVHD. The anti-leukemia effect 
by CD62L was associated only with the HLA-A3-like and/or B44-like super families, 
which are grouped as HLA class I alleles based on the similarity of their peptide binding 
motifs12).  Since these phenomenon has been described with respect to CTL lines that 
are specific for melanoma-associated antigens within the A2-like superfamily 18) and to 
HIV-specific peptides within the A3-like superfamily 19), molecules from incompatible 
CD62L and CD31 combination could be an immunodominant mHag in HLA identical 
stem cell recipients. 
 From these data we suggested that polymorphic adhesion molecule such as CD62L, 
CD31 codon 563 and codon 125 could function as immunodominant mHag to induce 
GVL effect rather than a-GVHD in the Japanese patients transplanted from 
HLA-identical stem cell grafts and contribute to long-term survival. To confirm this 
hypothesis, prospective randomized study is needed. Detection of the mHag specific 
cytotoxic T cells in a patient transplanted from the mHag negative graft is now under 
investigation.  
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Titles and legends 
Figure1; Probability of survival and accumulated rate of relapse among mHag 
incompatible and compatible patients in standard risk group. 
 
Legend; Total 63 cases were studied where 88% of 10 year survival and 22% of 
accumulated rate of relapse in mHag incompatible patients comparing to 64% of 10 
year survival (P < 0,03) and 66% of accumulated of relapse (P < 0,02) in mHag 
compatible patients after HLA identical SCT. 
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Table1 Characteristics of mHag incompatible and compatible patients.P1)P 
mHag compatibility 
 IC C 
 All patients 106 36 70 
Sex, n (%) 
 Male 65 21(58.3) 44(62.9) 
 Female 41 15(40.5) 26(37.1) 
Diagnosis, n (%) 
 ALL 27 7(19.4) 20(28.6) 
 AML  29 11(29.7) 18(25.7) 
 CML 34 9(24.3) 25(35.7) 
 HD 1 0(0) 1(1.42) 
 NHL 5 2(5.40) 3(4.29) 
 MDS 10 7(18.9) 3(4.29) 
Source of BMT, n (%) 
 Sibling            60 22(61.1) 38(54.2) 
 Unrelated donor 46 14(37.8) 32(45.7) 
Source of stem cell, n (%) 
 BM 88 29(80.5) 59(84.3) 
 PBSC 15 4(10.8) 11(15.7) 
 BM+PBSC   3 3(8.10) 0(0) 
Risk at transplantation, n (%) 
 Standard 63 19(51.4) 44(62.9) 
 High 42 17(47.2) 25(35.7) 
 Not evaluated   1 0(0) 1(1.42) 
Complications, n (%) 
 Relapse  33 6(16.7) P2) P 27(38.6) 
 Acute GVHD(≧2) 35 12(33.3) 23(32.9) 
 Chronic GVHD 52 17(47.2) 35(50.0) 
Direction of transplantation, n (%) 
 Female to male 25 9(25.0) 16(22.9) 
 Other 81 27(73.0) 54(77.1) 
Time of transplantation, n (%) 
 1985—1997 35 13(36.1) 32(45.7) 
 1998—2002 61 23(62.2) 38(54.3) 
Immunosuppressant, n (%) 
 Short term MTX+CyA 98 33(89.2) 65(92.8) 
 Short term MTX+FK 5 3(8.10) 2(2.86) 
 OtherP2） P 3 0(0) 3(4.29) 
Irradiation, n (%) 
 TBI 97 34(94.4) 63(90.0) 
 Non-TBI 9 2(5.40) 7(10.0) 
1） ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, 
chronic myelogenous leukemia; HD, Hodgkin’s disease; NHL, non-Hodgkin’s 
lymphoma; MDS, myelodysplastic syndrome and MDS including 4 refractory 
anemia, 4 refractory anemia with excessive blasts, 1 refractory anemia with 
excessive blasts in transformation and 2 overt leukemia; IC, incompatible; C, 
compatible; TBI, total body irradiation. MTX, Methotrexate; CyA, Cyclosporine, 
FK, Tacrolimus hydrate; PSL, prednisolone 
2） Short term MTX+PSL, CyA, MTX 
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